WINTON GROUP Ltd Sells 29,978 Shares of Arcus Biosciences, Inc. $RCUS

WINTON GROUP Ltd trimmed its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 32.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 62,251 shares of the company’s stock after selling 29,978 shares during the quarter. WINTON GROUP Ltd owned 0.06% of Arcus Biosciences worth $1,483,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in RCUS. Hantz Financial Services Inc. raised its holdings in shares of Arcus Biosciences by 121.9% in the fourth quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $38,000 after acquiring an additional 881 shares in the last quarter. SBI Securities Co. Ltd. raised its holdings in shares of Arcus Biosciences by 13,547.6% in the third quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock valued at $39,000 after acquiring an additional 2,845 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Arcus Biosciences by 17.5% in the fourth quarter. GAMMA Investing LLC now owns 3,230 shares of the company’s stock valued at $77,000 after acquiring an additional 482 shares in the last quarter. Abich Financial Wealth Management LLC bought a new stake in shares of Arcus Biosciences in the third quarter valued at about $69,000. Finally, Bayforest Capital Ltd bought a new stake in shares of Arcus Biosciences in the fourth quarter valued at about $190,000. 92.89% of the stock is currently owned by institutional investors.

Arcus Biosciences Price Performance

Shares of RCUS stock opened at $23.26 on Tuesday. Arcus Biosciences, Inc. has a fifty-two week low of $7.91 and a fifty-two week high of $28.72. The firm has a market capitalization of $2.92 billion, a price-to-earnings ratio of -7.31 and a beta of 0.85. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.04 and a current ratio of 4.04. The stock’s 50-day simple moving average is $23.88 and its 200-day simple moving average is $22.87.

Arcus Biosciences (NYSE:RCUS) last released its earnings results on Tuesday, May 5th. The company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.10). Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The firm had revenue of $17.00 million for the quarter, compared to analyst estimates of $29.49 million. During the same period last year, the firm earned ($1.14) EPS. The company’s revenue for the quarter was down 39.3% compared to the same quarter last year. As a group, equities analysts forecast that Arcus Biosciences, Inc. will post -3.61 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CAO Alexander Azoy sold 2,562 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $25.77, for a total transaction of $66,022.74. Following the completion of the transaction, the chief accounting officer directly owned 39,581 shares of the company’s stock, valued at $1,020,002.37. This represents a 6.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Robert C. Goeltz II sold 7,763 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $25.63, for a total value of $198,965.69. Following the sale, the chief financial officer owned 84,161 shares of the company’s stock, valued at $2,157,046.43. The trade was a 8.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on RCUS shares. Morgan Stanley lifted their price objective on Arcus Biosciences from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Monday, May 11th. Truist Financial initiated coverage on Arcus Biosciences in a report on Monday, May 18th. They issued a “buy” rating and a $35.00 price objective for the company. The Goldman Sachs Group increased their target price on Arcus Biosciences from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 target price on shares of Arcus Biosciences in a research report on Monday, March 2nd. Finally, Leerink Partners set a $47.00 target price on Arcus Biosciences in a research report on Monday, April 20th. Eight analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Arcus Biosciences currently has an average rating of “Moderate Buy” and an average price target of $35.10.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.